PDLI Financial Facts
Royalties: 83.37MNet income: 45.92M
See Full Income Statement
Other long-term liabilities: 24.83M
Total assets: 270.53M
See Full Balance Sheet
PDL BioPharma, Inc. (PDLI) Earnings
|
Expand Research on PDLI
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | -577.5% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -7.3% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
11/9/20  |
 |
Q320 | N/A | $0.06 | N/A | N/A | $5.5M | N/A | N/A | N/A | |
| 8/6/20 | |
Q220 | -$0.11 | $0.10 | -$0.21 | $5.21M | $1.5M | N/A |  | | Details |
| 5/7/20 | |
Q120 | -$0.26 | $0.05 | -$0.31 | $6M | $37.62M | N/A | | | Details |
| 3/11/20 | |
Q419 | -$0.48 | $0.05 | -$0.53 | N/A | $37.7M | N/A | | | Details |
| 11/6/19 | |
Q319 | -$0.16 | $0.05 | -$0.21 | $44.2M | $33.86M | N/A | | | Details |
| 8/7/19 |
|
Q219 | N/A | $0.04 | N/A | N/A | $31.74M | N/A | N/A | N/A | |
| 5/9/19 |
|
Q119 | N/A | $0.08 | N/A | N/A | $34.68M | N/A | N/A | N/A | |
| 3/14/19 | |
Q418 | $0.11 | $0.08 | +$0.03 | $45.12M | $46.08M | N/A | | | Details |
